Drug Profile


Alternative Names: KD-019; KD-020; Tesevatinib tosylate; XL-647

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Exelixis
  • Developer Exelixis; Kadmon Pharmaceuticals
  • Class Amines; Antineoplastics; Cyclopentanes; Pyrroles; Quinazolines; Small molecules
  • Mechanism of Action EphB4 inhibitors; Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Organic cation transport protein modulators; Src-Family kinase inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Autosomal dominant polycystic kidney disease; Glioblastoma
  • Phase I/II Breast cancer
  • Preclinical Autosomal recessive polycystic kidney disease
  • No development reported Hepatocellular carcinoma; Prostate cancer

Most Recent Events

  • 15 May 2017 Kadmon plans a phase II trial for Autosomal dominant polycystic kidney disease
  • 03 Apr 2017 Kadmon plans a phase I trial for Autosomal recessive polycystic kidney disease in USA (PO) (NCT03096080)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top